{
    "clinical_study": {
        "@rank": "10009", 
        "acronym": "ADACCESS", 
        "arm_group": [
            {
                "arm_group_label": "GP2017 Adalimumab", 
                "arm_group_type": "Experimental", 
                "description": "Study arm with intervention being studied in the protocol.  Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 33."
            }, 
            {
                "arm_group_label": "Humira \u00ae Adalimumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Humira\u00ae Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 33."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to demonstrate equivalent efficacy and similarity in the safety\n      profile of GP2017 and Humira\u00ae in patients with moderate to severe chronic plaque-type\n      psoriasis."
        }, 
        "brief_title": "Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Type Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women at least 18 years of age at time of screening\n\n          -  Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization\n\n          -  Moderate to severe psoriasis as defined at baseline by:\n\n               -  PASI score of 12 or greater\n\n               -  Investigator\u00b4s Global Assessment score of 3 or greater (based on a scale of 0 -\n                  4) and,\n\n               -  Body Surface Area affected by plaque-type psoriasis of 10% or greater\n\n          -  Chronic plaque-type psoriasis patients who have previously received phototherapy or\n             systemic psoriasis therapy at least once or who are candidates for such therapies in\n             the opinion of the investigator.\n\n        Exclusion Criteria:\n\n          -  Forms of psoriasis other than chronic plaque-type\n\n          -  Drug-induced psoriasis\n\n          -  Ongoing use of prohibited psoriasis treatments\n\n          -  Previous exposure to adalimumab\n\n          -  Active ongoing inflammatory diseases other than psoriasis that might confound the\n             evaluation of the benefit of treatment with adalimumab\n\n        Other In-/Exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "448", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016105", 
            "org_study_id": "GP17-301", 
            "secondary_id": "2013-000747-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "GP2017 Adalimumab", 
                "intervention_name": "GP2017 Adalimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Humira \u00ae Adalimumab", 
                "intervention_name": "Humira \u00ae Adalimumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "plaque type psoriasis", 
            "equivalent efficacy", 
            "safety and immunogenicity", 
            "GP2017", 
            "Humira\u00ae"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "last_name": "Dr. Selenkova"
            }, 
            "facility": {
                "address": {
                    "city": "Svidnik", 
                    "country": "Slovakia", 
                    "zip": "08901"
                }, 
                "name": "SANARA s.r.o, Dermatovenerologicka Ambulancia"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Slovakia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira\u00ae in Patients With Moderate to Severe Chronic Plaque-type Psoriasis", 
        "overall_contact": {
            "last_name": "Karsten Roth, Dr.", 
            "phone": "+498024476-0"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Bulgarian Drug Agency", 
                "Germany: Paul-Ehrlich-Institut", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Slovakia: State Institute for Drug Control", 
                "United States: Food and Drug Administration", 
                "India: Ministry of Health", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome measure is the PASI 75 response rate", 
            "safety_issue": "No", 
            "time_frame": "Week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PASI 50, 75, 90 and 100 will be assessed", 
                "measure": "PASI response rates", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1,3,5,7,9,11,13, 15,16,17"
            }, 
            {
                "measure": "Change from baseline in IGA", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 3, 5, 7, 9, 11, 13, 15, 16 and 17"
            }, 
            {
                "measure": "Patient't health related quality of life (HRQoL)", 
                "safety_issue": "No", 
                "time_frame": "Week 11 and 16"
            }
        ], 
        "source": "Sandoz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}